Diversify Wealth Management LLC Purchases 10,371 Shares of Halozyme Therapeutics, Inc. $HALO

Diversify Wealth Management LLC increased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 49.1% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 31,504 shares of the biopharmaceutical company’s stock after purchasing an additional 10,371 shares during the period. Diversify Wealth Management LLC’s holdings in Halozyme Therapeutics were worth $1,987,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Empowered Funds LLC purchased a new stake in Halozyme Therapeutics during the 1st quarter valued at about $755,000. Acadian Asset Management LLC purchased a new position in Halozyme Therapeutics in the 1st quarter worth approximately $195,000. Hsbc Holdings PLC lifted its position in Halozyme Therapeutics by 117.1% in the second quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock valued at $522,000 after purchasing an additional 5,448 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in Halozyme Therapeutics by 6.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 174 shares during the last quarter. Finally, Baird Financial Group Inc. boosted its stake in shares of Halozyme Therapeutics by 6.2% during the second quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock valued at $577,000 after purchasing an additional 650 shares during the period. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $76.11 on Tuesday. Halozyme Therapeutics, Inc. has a 12 month low of $55.64 and a 12 month high of $82.26. The stock has a market cap of $9.03 billion, a PE ratio of 27.38, a price-to-earnings-growth ratio of 0.32 and a beta of 0.84. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81. The company’s fifty day moving average price is $71.14 and its 200-day moving average price is $69.98.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. During the same quarter in the prior year, the business posted $1.11 EPS. The firm’s quarterly revenue was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, equities analysts expect that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current fiscal year.

Wall Street Analyst Weigh In

HALO has been the topic of a number of recent analyst reports. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, May 12th. UBS Group reaffirmed a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Morgan Stanley dropped their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Finally, HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, June 16th. Eight equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $81.60.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CEO Helen Torley sold 1,923 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $79.77, for a total value of $153,397.71. Following the completion of the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $61,245,810.60. The trade was a 0.25% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics stock in a transaction on Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the sale, the director directly owned 14,462 shares of the company’s stock, valued at $1,084,650. The trade was a 33.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 74,102 shares of company stock valued at $5,205,798. Corporate insiders own 2.50% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.